Compounds > 1-phenyl-2-decanoylamino-3-morpholino-1-propanol

1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Parkinsonian Disorders

1-phenyl-2-decanoylamino-3-morpholino-1-propanol has been researched along with Parkinsonian Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Anada, Y; Anderson, DW; Bradbury, KA; Inokuchi, J; Schneider, JS	1

Other Studies

1 other study(ies) available for 1-phenyl-2-decanoylamino-3-morpholino-1-propanol and Parkinsonian Disorders

Article	Year
The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism. Brain research, 2006, Jul-12, Volume: 1099, Issue:1 Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Morpholines; Neurons; Parkinsonian Disorders	2006

Article

Year

The synthetic ceramide analog L-PDMP partially protects striatal dopamine levels but does not promote dopamine neuron survival in murine models of parkinsonism.

Brain research, 2006, Jul-12, Volume: 1099, Issue:1

Topics: Animals; Cell Count; Cell Death; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Male; Mice; Mice, Inbred C57BL; Morpholines; Neurons; Parkinsonian Disorders

2006